High density lipoprotein cholesterol level is a robust predictor of lipid peroxidation irrespective of gender, age, obesity, and inflammatory or metabolic biomarkers

Clinica Chimica Acta

Volumn 412, Issue 15-16, 2011, Pages 1345-1349

  Zelzer, Sieglinde ^a   Fuchs, Nina ^a   Almer, Gunter ^a   Raggam, Reinhard B ^a   Prüller, Florian ^a   Truschnig Wilders, Martie ^a   Schnedl, Wolfgang ^b   Horejsi, Renate ^a   Möller, Reinhard ^a   Weghuber, Daniel ^c   Ille, Rottraut ^d   Mangge, Harald ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b Practice for General Internal Medicine   (Austria)

^c Paracelsus Private Medical School   (Austria)

^d UNIVERSITY OF GRAZ   (Austria)

Author keywords

HDL cholesterol; Obesity; Oxidized LDL

Indexed keywords

ADIPOCYTOKINE; BIOLOGICAL MARKER; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADOLESCENT; ADULT; AGE; ARTERIAL WALL THICKNESS; ARTICLE; CHILD; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; LIPID PEROXIDATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ADULT; AGE FACTORS; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; CHOLESTEROL, HDL; COHORT STUDIES; FEMALE; HUMANS; INFLAMMATION; LIPID PEROXIDATION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SEX FACTORS; YOUNG ADULT;

EID: 79956334078     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.03.031     Document Type: Article

References (31)

1. Ishigaki Y., Oka Y., Katagiri H. Circulating oxidized LDL: a biomarker and a pathogenic factor. Curr Opin Lipidol 2009, 20:363-369.
2. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med 2002, 8:1211-1217.
3. Kugiyama K., Kerns S.A., Morrisett J.D., Roberts R., Henry P.D. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 1990, 344:160-162.
4. Stiko-Rahm A., Hultgardh-Nilsson A., Regnstrom J., Hamsten A., Nilsson J. Native and oxidized LDL enhances production of PDGF AA and the surface expression of PDGF receptors in cultured human smooth muscle cells. Arterioscler Thromb 1992, 12:1099-1109.
5. Yui S., Sasaki T., Miyazaki A., Horiuchi S., Yamazaki M. Induction of murine macrophage growth by modified LDLs. Arterioscler Thromb 1993, 13:331-337.
6. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989, 320:915-924.
7. Galle J., Hansen-Hagge T., Wanner C., Seibold S. Impact of oxidized low density lipoprotein on vascular cells. Atherosclerosis 2006, 185:219-226.
8. Itabe H., Yamamoto H., Imanaka T., et al. Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J Lipid Res 1996, 37:45-53.
9. Njajou O.T., Kanaya A.M., Holvoet P., et al. Association between oxidized LDL, obesity and type 2 diabetes in a population-based cohort, the Health, Aging and Body Composition Study. Diabetes Metab Res Rev 2009, 25:733-739.
10. Shoji T., Nishizawa Y., Fukumoto M., et al. Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects. Atherosclerosis 2000, 148:171-177.
11. Fraley A.E., Tsimikas S. Clinical applications of circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease. Curr Opin Lipidol 2006, 17:502-509.
12. Khera A.V., Cuchel M., de la Llera-Moya M., et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011, 364:127-135.
13. Graham A., Hassall D.G., Rafique S., Owen J.S. Evidence for a paraoxonase-independent inhibition of low-density lipoprotein oxidation by high-density lipoprotein. Atherosclerosis 1997, 135:193-204.
14. Ferretti G., Bacchetti T., Masciangelo S., Bicchiega V. HDL-paraoxonase and membrane lipid peroxidation: a comparison between healthy and obese subjects. Obesity (Silver Spring) 2010, 18:1079-1084.
15. Alberti K.G., Zimmet P., Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006, 23:469-480.
16. Zimmet P., KG MMA, Serrano Rios M. A new international diabetes federation worldwide definition of the metabolic syndrome: the rationale and the results. Rev Esp Cardiol 2005, 58:1371-1376.
17. Moller R., Tafeit T.E., Sudi T.K., Reibnegger G. Quantifying the 'appleness' or 'pearness' of the human body by subcutaneous adipose tissue distribution. Ann Hum Biol 2000, 27:47-55.
18. Moeller R., Horejsi R., Pilz S., et al. Evaluation of risk profiles by subcutaneous adipose tissue topography in obese juveniles. Obesity (Silver Spring) 2007, 15:1319-1324.
19. Kiechl S., Willeit J. The natural course of atherosclerosis. Part II: vascular remodeling. Bruneck Study Group. Arterioscler Thromb Vasc Biol 1999, 19:1491-1498.
20. Pignoli P., Tremoli E., Poli A., Oreste P., Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 1986, 74:1399-1406.
21. Winkelmann B.R., Marz W., Boehm B.O., et al. Rationale and design of the LURIC study-a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics 2001, 2:S1-S73.
22. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
23. Holvoet P., De Keyzer D., Jacobs D.R. Oxidized LDL and the metabolic syndrome. Future Lipidol 2008, 3:637-649.
24. Holvoet P. Obesity, the metabolic syndrome, and oxidized LDL. Am J Clin Nutr 2006, 83:1438. author reply 1438-1439.
25. Ezgu F., Tumer L., Ozbay F., Hasanoglu A., Biberoglu G., Aybay C. Homocysteine, fibrinogen and anti-ox-LDL antibody levels as markers of atherosclerosis in prepubertal obese children. J Pediatr Endocrinol Metab 2009, 22:915-920.
26. Holvoet P. Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease. Verh K Acad Geneeskd Belg 2008, 70:193-219.
27. Norris A.L., Steinberger J., Steffen L.M., Metzig A.M., Schwarzenberg S.J. Circulating Oxidized LDL and Inflammation in Extreme Pediatric Obesity. Obesity (Silver Spring) 2011, ahead of print PMID: 21331062.
28. Kelly A.S., Jacobs D.R., Sinaiko A.R., Moran A., Steffen L.M., Steinberger J. Relation of circulating oxidized LDL to obesity and insulin resistance in children. Pediatr Diabetes 2010, 11:552-555.
29. Hirowatari Y., Tsunoda Y., Ogura Y., Homma Y. Analyzing of high-density lipoprotein subfractions and low-density lipoprotein subfractions in human serum with anion-exchange chromatography. Atherosclerosis 2009, 204:e52-e57.
30. Hulthe J., Fagerberg B. Circulating oxidized LDL is associated with increased levels of cell-adhesion molecules in clinically healthy 58-year old men (AIR study). Med Sci Monit 2002, 8:CR148-CR152.
31. Langlois M.R., Rietzschel E.R., De Buyzere M.L., et al. Femoral plaques confound the association of circulating oxidized low-density lipoprotein with carotid atherosclerosis in a general population aged 35 to 55years: the Asklepios Study. Arterioscler Thromb Vasc Biol 2008, 28:1563-1568.